RTP Mobile Logo

Friday, November 30, 2018, San Diego, California, 6:00 PM – 9:00 PM

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis (Part 2 of a 2-Part Series)

A Friday Satellite Symposia Series Preceding the 60th ASH Annual Meeting

This activity, the second of a 2-part series, will focus on common practical issues and challenges faced by clinicians caring for patients with multiple myeloma and the related disorders Waldenström macroglobulinemia and amyloidosis. Five world-renowned investigators will serve as the faculty. Leading up to the event, Research To Practice will recruit 6 community-based medical and hematologic oncologists to participate in a unique assessment to identify specific clinical situations or questions related to the management of these diseases for which they would seek investigator input. The meeting will be divided into 5 distinct topic modules, each featuring each featuring a discussion of the questions and issues provided by the consulting clinicians and a faculty member-led review of ongoing research. To cultivate a more interactive experience, clinicians in attendance will use networked iPads® to complete a survey featuring a number of the questions and topics to be discussed, the results of which will be presented and discussed throughout the program.

Event Details

Location:
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Hotel Phone: (619) 232-1234

Event Times:
6:00 PM – 6:30 PM — Registration and Dinner Buffet
6:30 PM – 9:00 PM — Educational Meeting

Meeting Room:
Harbor Ballroom (Second Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Faculty:
Rafael Fonseca, MD
Getz Family Professor of Cancer
Chair, Department of Internal Medicine
Mayo Clinic Arizona
Scottsdale, Arizona

Sagar Lonial, MD
Professor and Executive Vice Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Chair Ad Interim, Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas


Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Professor Katja Weisel, MD
Professor of Medicine
University Hospital Tübingen
Tübingen, Germany

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida



Agenda

6:00 PM – 6:30 PM — Registration and Dinner Buffet
6:30 PM – 9:00 PM — Educational Meeting

  • Module 1: Evolving treatment paradigms in the management of multiple myeloma (MM); role of minimal residual disease assessment in informing therapeutic decision-making in the front-line setting and beyond
  • Module 2: Available and emerging research data with novel induction (eg, “RVD-lite,” KRd, VMP/daratumumab, etc) and maintenance approaches for patients with newly diagnosed MM; ongoing Phase III clinical trials
  • Module 3: Management of relapsed/refractory MM: Impact of prior therapeutic exposure, disease-free interval, cytogenetic status and symptomatology on therapeutic selection and sequencing
  • Module 4: Early activity and safety with and ongoing evaluation of promising novel agents and immunotherapeutic strategies for patients with MM
  • Module 5: Clinical and biologic considerations in the long-term management of amyloidosis and Waldenström macroglobulinemia; role of new agents and strategies

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis (AL).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory (R/R) MM.
  • Appreciate the mechanisms of action of, supportive research database with and FDA-endorsed indications for monoclonal antibodies directed at CD-38 and SLAM-F7, and effectively identify where and how these agents should be integrated into the clinical management of R/R MM.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies to support quality of life and continuation of treatment.
  • Develop an evidence-based algorithm for the use of stem cell transplant, chemotherapy and/or novel targeted agents for the management of primary AL.
  • Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for patients with WM requiring active treatment.
  • Assess the ongoing clinical trials evaluating novel investigational approaches for MM, WM and AL, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from AbbVie Inc, Acerta Pharma – A member of the AstraZeneca Group, Adaptive Biotechnologies, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

Location

Location:
Manchester Grand Hyatt San Diego
1 Market Place
San Diego, CA 92101
Hotel Phone: (619) 232-1234

Meeting Room:
Harbor Ballroom (Second Level)

Directions:
The Manchester Grand Hyatt San Diego hotel is conveniently located within walking distance of the San Diego Convention Center, where the ASH Annual Meeting is taking place.

Registration

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma, Waldenström macroglobulinemia and amyloidosis.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.